These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38800235)

  • 21. Precursor B cell lymphoid blast crisis of chronic myeloid leukemia with novel chromosomal abnormalities: A case report.
    Al-Khallaf H; Alali H; Alkhatti A
    Oncol Lett; 2018 Nov; 16(5):6691-6696. PubMed ID: 30405810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. B-Lymphoid Blast Phase of Chronic Myeloid Leukemia: A Case Report and Review of the Literature.
    Ware AD; Wake L; Brown P; Webster JA; Smith BD; Duffield AS
    AJSP Rev Rep; 2019; 24(5):191-195. PubMed ID: 32656356
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
    Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Venetoclax and BCR-ABL Tyrosine Kinase Inhibitor Combinations: Outcome in Patients with Philadelphia Chromosome-Positive Advanced Myeloid Leukemias.
    Maiti A; Franquiz MJ; Ravandi F; Cortes JE; Jabbour EJ; Sasaki K; Marx K; Daver NG; Kadia TM; Konopleva MY; Masarova L; Borthakur G; DiNardo CD; Naqvi K; Pierce S; Kantarjian HM; Short NJ
    Acta Haematol; 2020; 143(6):567-573. PubMed ID: 32289808
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Blast phase of chronic myeloid leukemia with concurrent BCR::ABL1 and SET::NUP214: A report of two cases.
    Chen Y; Wang Q; Cen J; Xu C; Tao TT; Xie J; Shen W; Gong Y; Pan J; Yao L
    Mol Carcinog; 2023 Feb; 62(2):117-121. PubMed ID: 36321418
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation.
    Kawano N; Okuda S; Yoshida S; Kugimiya H; Ito M; Horikawa N; Chosa N; Hisakata T; Fukudome T; Sakurai R; Yamashita K; Ueda A; Kanda Y
    Int J Hematol; 2011 Dec; 94(6):561-6. PubMed ID: 22057509
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2022 Sep; 97(9):1236-1256. PubMed ID: 35751859
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Chronic myeloid leukemia with pure erythroid leukemia blast crisis.
    Jacobs JW; Ramaswamy R; States V; Reppucci J; Oluwole OO; Mason EF; Thompson MA
    Leuk Lymphoma; 2022 Jan; 63(1):212-216. PubMed ID: 34486918
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dasatinib rapidly induces deep molecular response in chronic-phase chronic myeloid leukemia patients who achieved major molecular response with detectable levels of BCR-ABL1 transcripts by imatinib therapy.
    Shiseki M; Yoshida C; Takezako N; Ohwada A; Kumagai T; Nishiwaki K; Horikoshi A; Fukuda T; Takano H; Kouzai Y; Tanaka J; Morita S; Sakamoto J; Sakamaki H; Inokuchi K
    Int J Clin Oncol; 2017 Oct; 22(5):972-979. PubMed ID: 28550414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Coexistence of P190 and P210 BCR/ABL transcripts in chronic myeloid leukemia blast crisis resistant to imatinib.
    Junmei Z; Fengkuan Y; Yongping S; Baijun F; Yuzhang L; Lina L; Qinglan Z
    Springerplus; 2015; 4():170. PubMed ID: 25897414
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triptolide induces cell death independent of cellular responses to imatinib in blast crisis chronic myelogenous leukemia cells including quiescent CD34+ primitive progenitor cells.
    Mak DH; Schober WD; Chen W; Konopleva M; Cortes J; Kantarjian HM; Andreeff M; Carter BZ
    Mol Cancer Ther; 2009 Sep; 8(9):2509-16. PubMed ID: 19723894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activation of EVI1 transcription by the LEF1/β-catenin complex with p53-alteration in myeloid blast crisis of chronic myeloid leukemia.
    Manachai N; Saito Y; Nakahata S; Bahirvani AG; Osato M; Morishita K
    Biochem Biophys Res Commun; 2017 Jan; 482(4):994-1000. PubMed ID: 27908728
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overview of clinical and genetic features of CML patients with variant Philadelphia translocations involving chromosome 7: A case series.
    Bayrak AG; Daglar Aday A; Yavuz AS; Nalcaci M; Ozbalak MM; Cefle K; Ozturk S; Palanduz S
    Leuk Res; 2021 Dec; 111():106725. PubMed ID: 34634595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
    Jabbour E; Kantarjian H
    Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions.
    Osman AEG; Deininger MW
    Blood Rev; 2021 Sep; 49():100825. PubMed ID: 33773846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Additional chromosome abnormalities, BCR-ABL tyrosine kinase domain mutations and clinical outcome in Hungarian tyrosine kinase inhibitor-resistant chronic myelogenous leukemia patients.
    Meggyesi N; Kozma A; Halm G; Nahajevszky S; Bátai A; Fekete S; Barta A; Ujj G; Lueff S; Sipos A; Adám E; Bors A; Reményi P; Masszi T; Tordai A; Andrikovics H
    Acta Haematol; 2012; 127(1):34-42. PubMed ID: 22005133
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A unique case of complex variant translocation of t(6;9;22)(p22;q34;q11.2), der(19) in a newly diagnosed patient with chronic myeloid leukemia.
    Ciftciler R; Saglam EA; Inanc A; Ozcebe O; Haznedaroglu IC
    Cancer Genet; 2019 Sep; 237():78-81. PubMed ID: 31447069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted chronic myeloid leukemia therapy: Seeking a cure.
    Fausel C
    Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S9-15. PubMed ID: 18056932
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Successful treatment with nilotinib after imatinib failure in a CML patient with a four-way Ph chromosome translocation and point mutations in BCR/ABL gene.
    Okada M; Satake A; Kaida K; Taniguchi K; Yoshihara S; Ikegame K; Tamaki H; Soma T; Fujimori Y; Ogawa H
    Int J Hematol; 2011 Feb; 93(2):243-246. PubMed ID: 21279819
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined inhibition of β-catenin and Bcr-Abl synergistically targets tyrosine kinase inhibitor-resistant blast crisis chronic myeloid leukemia blasts and progenitors in vitro and in vivo.
    Zhou H; Mak PY; Mu H; Mak DH; Zeng Z; Cortes J; Liu Q; Andreeff M; Carter BZ
    Leukemia; 2017 Oct; 31(10):2065-2074. PubMed ID: 28321124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.